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Abstract: Photodynamic priming (PDP), a collateral effect
of photodynamic therapy, can transiently alter the tumor
microenvironment (TME) beyond the cytotoxic zone. Studies
have demonstrated that PDP increases tumor permeability
and modulates immune-stimulatory effects by inducing
immunogenic cell death, via the release of damageassociated molecular patterns and tumor-associated antigens. Pancreatic ductal adenocarcinoma (PDAC) is one of
the deadliest of cancers with a stubborn immunosuppressive TME and a dense stroma, representing a challenge
for current molecular targeted therapies often involving
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macromolecules. We, therefore, tested the hypothesis that
PDP’s TME modulation will enable targeted therapy and
result in immune stimulation. Using triple-receptor-targeted
photoimmuno-nanoconjugate (TR-PINs)-mediated PDP,
targeting epidermal growth factor receptor, transferrin receptor, and human epidermal growth factor receptor 2 we
show light dose-dependent TR-PINs mediated cytotoxicity
in human PDAC cells (MIA PaCa-2), co-cultured with human
pancreatic cancer-associated ﬁbroblasts (PCAFs) in spheroids. Furthermore, TR-PINs induced the expression of heat
shock proteins (Hsp60, Hsp70), Calreticulin, and high
mobility group box 1 in a light dose and time-dependent
manner. TR-PINs-mediated T cell activation was observed in
co-cultures of immune cells with the MIA PaCa-2-PCAF
spheroids. Both CD4+ T and CD8+ T cells showed light dose
and time-dependant antitumor reactivity by upregulating
degranulation marker CD107a and interferon-gamma postPDP. Substantial tumor cell death in immune cell-spheroid
co-cultures by day 3 shows the augmentation by antitumor T
cell activation and their ability to recognize tumors for a
light dose-dependent kill. These data conﬁrm enhanced
destruction of heterogeneous pancreatic spheroids mediated by PDP-induced phototoxicity, TME modulation and
increased immunogenicity with targeted nanoconstructs.
Keywords: immunogenic cell death; multitargeting; photodynamic therapy; photoimmuno-nano-conjugates; T cell
priming; tumor heterogeneity.

1 Introduction
Photodynamic therapy (PDT), a Food and Drug Administration (FDA)-approved anticancer therapy is based on the
activation of a photosensitizer (PS) with an appropriate
wavelength of light, typically red light. Reactive molecular species (RMS) generated from the photodynamic
This work is licensed under the Creative Commons Attribution 4.0
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activation process then provide the cell killing and other
tumor modulation effects [1]. While classically, this is
thought to lead to photoablation of the tumor cells and
subsequent cell death either by direct cytotoxicity or
damage to the tumor vasculature, there is also a host of
sub-lethal cell signaling changes that alter the tumor
milieu. Responses to PDT may be modulated to a large
extent by varying the light dose, PS concentration, and
drug light interval (DLI). Due to its minimally invasive
properties as a therapeutic modality, PDT holds great
promise to be used in alternative treatments or in combination with other conventional anticancer treatments
such as surgery, chemotherapy, or radiotherapy [2]. It is
indeed approved for several indications by the regulatory
authorities worldwide. PDT-activated immune responses
are both local and extended systemically far beyond the
irradiated site [3, 4].
Preclinical and clinical studies have demonstrated
that PDT can affect both the innate and adaptive arms of
the immune system [3, 5–7]. These immune-stimulatory
effects occur through PDT’s ability to induce immunogenic
cell death (ICD), which increases the immunogenicity of
the tumor microenvironment (TME) by the release of
damage-associated molecular patterns (DAMPs) and
tumor-associated antigens (TAAs) [8, 9]. The degree of ICD
by PDT greatly depends on the release of RMS [10]. PDT can
induce a large amount of RMS production inside the cancer
cells, thereby causing oxidative stress-based cell death.
PDT generates DAMPs such as calreticulin (CRT), heat
shock proteins (Hsp60, Hsp70, and Hsp90), high mobility
group box 1(HMGB1), and extracellular ATP [8, 11, 12].
DAMPs and cytokines (such as tumor necrosis factor
(TNF)-α, interleukin (IL)-6, and IL-1β) released from PDT
treated cells cause acute inﬂammation and enhance
inﬁltration of innate and adaptive immune cells to the
irradiated tumor site [8, 13–18]. PDT enhances antigen
presentation by professional antigen-presenting cells
(APC), such as dendritic cells (DCs), whereby TAAs are
processed and presented to cells of the adaptive immune
system; especially T cells [9, 17, 19]. During PDT-mediated
release of DAMPs and subsequent inﬂammation, APCs
mature and migrate to the draining lymph nodes. This
transition of DCs involves their activation via the upregulation of major histocompatibility class I and II molecules
(MHC-I and MHC-II) and the costimulatory molecules
CD80 and CD86 on their cell surfaces. Once DCs are activated they are efﬁcient in priming CD4+ T helper cells and
CD8+ cytotoxic T lymphocytes (CTLs) by the presentation
of TAAs and initiate an effective adaptive immune
response. Antigen-experienced CTLs may migrate to the

tumor site to attack the remaining and/or metastasized
tumor cells [9]. Overall, PDT may turn “immune silent”
tumors into “immune responsive” tumors by inducing ICD
and enhanced immunogenicity following it.
Recent evidence shows that a collateral effect of a
sublethal dose of PDT termed photodynamic priming
(PDP) [20], confers increased immunogenicity [3, 21] by
priming multiple compartments in the TME. PDP-associated immune-stimulatory effects have been shown to
enhance the inﬁltration of neutrophils and activated CTLs
in the TME [3, 18, 21]. Also, our work in pancreatic ductal
adenocarcinoma (PDAC) murine models demonstrated
that PDP can prime multiple tumor compartments to
enable a more potent and sustained antitumor chemotherapeutic effect [20] or chemotherapy dose reduction
for improved tolerability [22]. PDAC is one of the most
lethal cancers with a low response to treatment of any
kind including immune therapies and a ﬁve-year survival
rate of around 10% [23]. PDAC pathophysiology is challenging for current therapies as immunosuppressive
desmoplastic stroma limits responsiveness to treatments
including macromolecular targeting and immunotherapy
[24–26].
Photoimmunoconjugates that target cell membrane
molecules overexpressed by cancer cells create a combined
photodynamic and receptor antagonist therapeutic agent
for tumor-targeted, activatable photoimmunotherapy (PIT)
[27]. NIR-PIT induces ICD and expression and translocation
of DAMPs followed by maturation of DCs, thus eliciting a
host immune response against the tumor [28]. Combined
with the molecular targeting ability of the receptortargeted nanoconstructs, PIT may be a powerful strategy
for inducing ICD in cancer therapy. However, despite
ongoing human trials (NCT02422979; PIT using a conjugate
of the silicon phthalocyanine PS derivative IRDye700DX
with cetuximab [Cet] [29]), complete tumor eradication is
hampered by intratumoral receptor heterogeneity, leading
to the survival of residual resistant tumor cells. The
inability to target multiple receptors simultaneously is a
clinical obstacle for optimal treatment outcomes due to the
heterogeneity of tumors with multiple survival pathways
being operative.
Recently, we reported the targeting of multiple receptors on tumor cells to address heterogeneity-driven
resistance to molecular targeted PDT. Red-activatable,
triple-receptor-targeted photoimmuno-nanoconjugates
(TR-PINs) platform conferred specificity for epidermal
growth factor receptor (EGFR), transferrin receptor
(TfR), and human epidermal growth factor receptor 2
(HER-2). Multi-targeting enhanced the specificity and
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Figure 1: Schematic concept of the study. Photodynamic priming (PDP) induces the expression of HSP60, HSP70, Calreticulin, and HMGB1 in
Panc spheroids, when treated with triple-receptor-targeted photoimmuno-nanoconjugates (TR-PINs). This highlights the direct tumor cell
killing and the induction of immunogenic cell death by TR-PINs, enhancing the immunogenicity of spheroids. Upregulation of degranulation
marker CD107a and interferon-gamma (IFNγ) in CD4+ T cells and CD8+ T cells demonstrates efﬁcient T cell priming due to enhanced immunogenicity. The direct phototoxic effects of TR-PINs and photo-primed antitumor T cells show substantial tumor cell death, suggesting
enhanced tumor killing.

overall completeness of PDT response in a heterogeneous tumor model of MIA PaCa-2 and T47D or SKOV-3
cells when compared to mono-targeting [30]. In this
study, we set out to establish whether PDP multiple
targeting of tumor cells can initiate an antitumor immune response by enhancing tumor immunogenicity
(Figure 1) while taking care of the heterogeneous cell
populations. Following covalent conjugation of functionalized ligands to the surface of photosensitizing
liposomal nanoconstructs, the innovative binding of
TR-PINs to the tumor cells was used to evaluate, PDT
efﬁcacy, associated immune-stimulatory effects, and the
degree of ICD induction in vitro three-dimensional (3D)
heterogeneous tumor model of PDAC and pancreatic
cancer-associated ﬁbroblasts (PCAFs). We quantiﬁed
the expression of Hsp60, Hsp70, CRT, and HMGB1. We
also investigated the efﬁcient priming of T cells and
their ability to perform further killing of malignant cells
by co-culturing MIA PaCa-2 and PCAFs with allogenic
human peripheral blood mononuclear cells (PBMC). For
clarity, we term heterocellular MIA PaCa-2-PCAF
spheroids as Pancreatic (Panc) spheroids and where
Panc spheroids are cocultured with immune cells as
Immune-Panc spheroids. TR-PINs were able to exert
direct cytotoxic effects followed by enhanced ICD in
Panc spheroids. We found marked enhancement of T
cell priming and effective tumor cell killing in PDT
treated Immune-Panc spheroids consistent with the
triggering an effective immune response to TR-PINs
mediated PDP.

2 Results and discussion
2.1 Design, preparation, and
characterization of TR-PINs
The preparation of TR-PINs (Figure 2(A)), is published [30].
Brieﬂy, the liposomal photosensitizing nanoconstructs
(PSNs) were formed, incorporating a lysophospholipid
anchored variant of the hydrophobic photosensitizer benzoporphyrin derivative (BPD), within the liposomal bilayer.
Lipidation of BPD had no impact on its absorption properties,
as determined by the lack of any spectral shifts [31, 32]. The
puriﬁed lipidated variant (BPD-PC) of PS was characterized
by Matrix Assisted Laser Desorption/Ionization (MALDI) to
verify molecular weight and by HPLC to assess purity [31, 32].
Moreover, BPD-PC containing photosensitizing liposomal
nanoconstructs remained colloidally stable with the BPD
inserted into the hydrophobic bilayer. When incubated with
OVCAR-5 cells, these liposomal nanoconstructs demonstrated no PS leaching [32]. As such the lipid anchoring
strategy adopted here, modulate the PS’s membrane stability,
and promote nanoconstruct integrity. Three ligands, Cet,
holo-transferrin (HT), and trastuzumab (TZ) (Figure 2(B)) were
modiﬁed and conjugated to the surface of the PSNs [30, 32].
Figure 2(C) provides details of the physical characterizations
that need to be carefully considered for the rational design of
targeted nanoconstructs. TR-PINs exhibit an average hydrodynamic size of 112.32 ± 6.0, with the polydispersity indices
0.01 ± 0.02 suggesting a narrow size distribution of liposomal
nanoconstructs. There was an average anionic ζ-potential of
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Figure 2: Schematic representation of the design of triple-receptor-targeted photoimmuno-nanoconjugates (TR-PINs).
Design of triple-receptor-targeted photoimmuno-nanoconjugates (TR-PINs) (A) and the ligands (B) conjugated via a copper-free click chemistry
approach. Physical characterization of the TR-PINs (C). TR-PINs exhibit a significant improvement in binding to MIA PaCa-2 cells (D). BPD-PC
emission intensities measured via flow cytometry were used to analyze TR-PINs cellular binding as compared to the photosensitizing
nanoconstructs (PSNs). Representative phototoxicity dose−response curves of the PSNs and the TR-PINs in MIA PaCa-2 monolayers (E). The
NIR photodynamic activation regimen employed 690 nm light irradiation and 20 J/cm2 at 150 mW/cm2 (mean ± SEM; n = 9–12 for a−c; one-way
ANOVA with a Tukey post-test; ∗∗∗∗P ≤ 0.0001, ∗∗∗P ≤ 0.001, ∗∗P ≤ 0.01).

−19.3 ± 1.3 mV, and 87 ± 6.2 stochastically oriented ligands
(Cet per TR-PIN = 24.5.0 ± 3.0, HT per TR-PIN = 30.9 ± 1.5,
and TZ per TR-PIN = 34.1.0 ± 3.2), on the surface of nanoconstructs. For enhanced PDT efﬁcacy, liposomal entrapped PS must be delivered and accumulated selectively in
targeted tumor cells, to avoid toxic effects in normal tissues. The liposomal membrane provides numerous
immobilization sites for recognition moieties such as antibodies, ligands, peptides, and electric charges [33], which
over the past few decades have provided innovative solutions for improved binding of multiple payloads to cancer
cells and circumventing off-target phototoxicity using
photoactivable liposomal-based nanoconstructs for cancer
cell targeting and the delivery of therapeutics [31–33].
Heterogeneous tumors such as PDAC exhibit patterns
of tumor-associated cell surface receptors (EGFR, TfR, and

HER-2) over-expression, and can be selectively targeted
using PDT, directed against these receptors. Specific
recognition of multiple cell surface targets may increase
the specificity of drug delivery and treatment efficacy in
heterogeneous tumor environments, thereby ultimately
mitigating treatment escape. Using the established EGFR
(1.7 × 105 EGFR/cell) expression levels in MIA PaCa-2 cells
we approximated that MIA PaCa-2 cells also express TfR
(1.9 × 106) and HER-2 (3.7 × 104), which is consistent with
our previous investigations [30, 32]. Similarly, relative cell
surface expression levels of EGFR, HER-2, and TfR in PCAF
cells are approximated using ﬂow cytometry to be 4.8 × 104,
1.5 × 106, and 6.7 × 104, respectively. It was found that the
simultaneous targeting of three receptors demonstrates
signiﬁcantly higher cellular binding of TR-PINs, relative to
the EGFR, TfR, and HER-2 hyperexpression in MIA PaCa-2
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cells. Triple-receptor targeting resulted in 45-fold (MIA
PaCa-2 cells) improvements in binding with targeting when
compared with the untargeted-PSNs (Figure 2(D)). CHO-WT
cells, being null for the three receptors do not show enhancements in binding with targeting using TR-PINs.
Similar results of higher binding with triple targeting
employing TR-PINs were observed previously for a panel of
cell lines including A431, T47D, SKOV-3, MIA PaCa-2, and
SCC-9, in comparison to mono receptor targeting with the
EGFR-speciﬁc PINs [30]. Furthermore, we compared the
efﬁcacy of molecularly targeted TR-PINs with an untargeted BPD-PC containing PSNs in MIA PaCa-2 cells (high in
EGFR, TfR, and HEER-2) using 690 nm light at an irradiance
of 150 mW/cm2 and a ﬂuence of 20 J/cm2. Targeting
improved the efﬁcacy of photodestruction signiﬁcantly
compared to the untargeted PSNs (Figure 2(E)). We also
compared the efﬁcacy of TR-PINs with an untargeted
BPD-PC containing PSNs in MIA PaCa-2 cells (high in EGFR,
TfR, and HER-2) using 690 nm light at an irradiance of 150
mW/cm2 and a ﬂuence of 20 J/cm2. Triple targeting using
TR-PINs improved the efﬁcacy of photodynamic activation
compared to the untargeted PSNs (Figure 2(E)), which is
consistent with its superior binding efﬁciencies (Figure
2(D)). For all TR-PINs concentrations tested, no dark
toxicity was observed [30].

2.2 NIR light-mediated photodynamic
treatment of 3D heterocellular Panc
spheroids
NIR light-triggered PIT combines the advantages of the targeting and NIR light, conferring the specificity with the
cytotoxicity of PDT to impart rapid and highly selective cell
death. However, targeted destruction with the higher specificity becomes the central challenge, while addressing the
resistance that arises from receptor heterogeneity. Multiple
studies have reported positivity up to 95% for EGFR [34, 35]
and 69% for HER-2 [36, 37] among patients with pancreatic
tumors. The expression makes EGFR and HER-2 potential
targets for light activatable molecular therapies. Because TfR
over-expression has also been reported in PDAC, we have
included TfR as an additional target. We had shown in earlier
reports that TR-PINs (EGFR, HER-2, and TfR speciﬁc) exhibit
expanded cancer cell binding speciﬁcities, enhanced cellular
uptake, and superior PDT response compared to the single
receptor-targeted therapy (speciﬁc for EGFR only) when
studied in complex heterogeneous tumor models comprising
MIA PaCa-2 cells and low-EGFR-expressing T47D or SKOV-3
cells [30]. Considering that EGFR, HER-2, and TfR over-
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expression is prevalent not only in PDAC but also in PCAFs
cells, we thus further evaluated the speciﬁcity of TR-PINs for
PS delivery and PDT efﬁcacy in a more complex heterocellular tumor model of PDAC and PCAFs. Heterocellular
spheroids of human PDAC (MIA PaCa-2 cells) and human
PCAF cells are referred to as Panc spheroids from hereon.
Established heterocellular Panc spheroids (MIA PaCa-2 and
PCAFs) were incubated for 6 h with untargeted-PSNs or
TR-PINs (0–1000 nM equivalent of BPD-PC), washed three
times to remove any unbound TR-PINs and then irradiated
with varying light doses (25 or 50 or 75 or 100 J/cm2) at an
irradiance of 150 mW/cm2. These parameters of incubation
time and irradiance previously allowed us to achieve sufﬁcient intracellular PS (BPD-PC) accumulation to enable a
potential PDT-enhancement effect while remaining nontoxic
for spheroids. Following PDT (Figure 3(A)), the spheroids
were co-stained with propidium iodide (Dead) Calcein AM
(Live) reagents before single-plane confocal imaging. Quantitative fractional viability heatmap images were generated
using a comprehensive high-throughput image analysis
procedure or structurally complex organotypic cultures for
the viability assessment of the tumor spheroids (Figure 3(B))
[38].
In the absence of photoactivation, neither untargeted
PSNs nor TR-PINs exerted any significant toxic effects on
heterogeneous Panc spheroids (Supplementary Figure 1)
[30, 32]. Untargeted PSNs also did not show any signiﬁcant
phototoxicity even at the highest concentration of 1000 nM
of BPD-PC equivalent (Supplementary Figure 2) at the
highest light dose of 100 J/cm2 (150 mW/cm2). Irradiation
(in the presence of TR-PINs) induced a PS dose-dependent
increase in spheroid necrosis, which was signiﬁcantly
higher in spheroids treated with the light dose of 100 J/cm2
(Figure 3(B)). In the Panc spheroids of MIA PaCa-2 and
PCAF, the EGFR-TfR-HER-2 speciﬁc TR-PINs were signiﬁcantly more effective in killing cancer cells than the
untargeted PSNs. Compared with low-TR-PINs concentration (50–100 nM of BPD-PC equivalent), NIR photodynamic
cytotoxicity using high-TR-PINs concentration (500–1000
nM of BPD-PC equivalent) was much stronger, exhibiting
dose-dependence at all light doses used. The Panc spheroids viability only decreased to 23% after PDT with the
TR-PINs concentration (100 nM of BPD-PC equivalent)
at a light dose of 100 J/cm2 (150 mW/cm2)
(Figure 3(A)). It is also evident that lower light doses (25 or
50 J/cm2; 150 mW/cm2) were not sufﬁcient to cause signiﬁcant differences in tumor cell viability when treated
with the higher TR-PINs concentration (1000 nM of BPD-PC
equivalent) in the heterocellular Panc spheroid model.
Even though a large proportion (43%) of tumor cells are
eradicated from the Panc spheroids of MIA PaCa-2 and
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Figure 3: Schematic representation of the culturing and treatment of heterocellular Panc (PDAC-PCAF) spheroids followed by an imagingbased analysis of treatment response.
A comprehensive image analysis procedure for structurally complex organotypic cultures was used for the quantitation of fractional viability of
spheroids following NIR photodynamic activation (A) using TR-PINs and PSNs (B). The NIR photodynamic activation regimen used was 690 nm

P. De Silva et al.: Photodynamic activation of Verteporfin to boost antitumor immunity

PCAFs, there are still residual cells remaining. Factors
including differences in light distribution and the reduction in the rate of 1O2 production [30] (in the presence of a
high number of ligands as in the case of TR-PINs) may
inﬂuence the improved PDT in heterocellular 3D spheroids.
In the absence of direct PS-only control it is difﬁcult to
make a deﬁnitive statement, as 3D tumor models, recapitulating the in vivo TME to a great extent are heterogenous.
Like a “real” tumor, the distribution of PS and light are not
identical from cell to cell. All these results in heterogeneous outcomes. Understanding the mechanisms for why
there remain residual tumor cells following treatment in
the heterocellular spheroids is critical and serves as the
focus of future studies.
Employing a light dose of 100 J/cm2 (150 mW/cm2) with
higher TR-PINs concentrations (1000 nM of BPD-PC
equivalent), led to an 80% reduction in Panc spheroid
viability after PDT (Figure 3(C)), suggesting potent cytotoxic effects of using a light dose of 100 J/cm2. Moreover,
∼60% reduction in spheroid viability was also observed
after PDT with the TR-PINs (250 nM of BPD-PC equivalent)
at a similar light dose of 100 J/cm2 (Figure 2(D)), suggesting
a combination of optimal TR-PINs concentration of 250 nM
(BPD-PC equivalent) and a light dose of 100 J/cm2 may
provide a better opportunity (Figure 3(D)) to understand
PDP of antitumor immune responses. Thus, we selected
TR-PINs (250 nM of BPD-PC equivalent) for subsequent
experiments. Together, these ﬁndings provide compelling
evidence for the potential of TR-PINs to enhance PDT efﬁcacy through a light dose-enhancement effect, encouraging further in vivo investigations.

2.3 TR-PINs mediated induction of ICD
Apart from direct tumor cell death, PDT has been reported
to induce ICD, characterized by the exposure or the release
of DAMPs from dying cells at the site of tumor irradiation [5,
39, 40]. These molecules alert the innate and adaptive arms
of the immune system about the tumor by triggering local
inﬂammation. DAMPs bind to cellular receptors (Toll-like
receptors) and activate the innate immune cells such as
macrophages or DCs which are highly specialized for presenting antigens to T cells, leading to T cell priming and
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enhanced ability to perform tumor cell killing.
PDT-mediated ICD induction seems to be dependent on the
type of PS (its cellular localization and PS concentration),
light dose, DLI, and tumor model among other factors [3].
Therefore, in Panc spheroids we explored the ability of
TR-PINs to induce ICD via the expression of previously
reported DAMPs that are considered as ‘’hallmarks of ICD,’’
including Hsp60, Hsp70, CRT, and HMGB1. We evaluated
the expression kinetics of these molecules by applying
varying light doses (25–100 J/cm2 at an irradiance of 150
mW/cm2) and analyzing the expression patterns at
different time points (1–72 h post-PDT) using multi-color
ﬂow cytometry. Using gating strategies shown in Supplementary Figure 3(A), we detected surface expression of
Hsp60, Hsp70, CRT, and intracellular expression of
HMGB1.
Our data show that illumination of TR-PINs was able to
induce the expression of Hsp60, Hsp70, CRT, and HMGB1
in a manner dependent upon light dose, PS concentration,
and time, suggesting that TR-PINs mediated ICD (Figure 4
and Supplementary Figure 3(B) and (C)). Median ﬂuorescence intensities (MFI) of CRT were comparatively higher
than respective MFI of Hsp60, Hsp70, and HMGB1 for all
light doses and TR-PINs concentrations. Hsp60 and Hsp70
were increased as early as 1 h post-PDT, with peak
expression for both at 1–6 h for both and decreasing at 72 h
relative to untreated controls or TR-PINs without light
activation (data not shown) (Figure 4). Both the 75 and 100
J/cm2 light doses were also effective in inducing high levels
of Hsp60 and Hsp70 at 1 and 6 h. The normal physiological
role of Hsp60 and Hsp70 is to protect cells exposed to
stressful conditions by safeguarding cell integrity and
maintaining functional signaling pathways that are critical
for cell survival and normal cell function [41, 42]. The
protective response of Hsps after PDT seems to depend
upon their cellular localization; intracellular localization
appears related to antiapoptotic function, whereas extracellular Hsps or membrane-bound Hsps mediate immunological functions [43, 44]. Oxidative damage to cells by
PDT-induced RMS modiﬁes cellular proteins via fragmentation, cross-linking, unfolding, and aggregation; in this
situation, Hsps identify unfolded proteins and help to
either refold them or remove them via complex proteolytic
systems. However, excessive accumulation of unfolded

light irradiation with 25 or 50 or 75 or 100 J/cm2 at 150 mW/cm2. Quantitation of fractional viability of MIA PaCa-2 and PCAFs spheroids
following NIR photodynamic activation (25, 50, 75, 100 J/cm2) at a log10 [BPD-PC] (nM) = 2.3 (250 nM of BPD-PC equivalent) using TR-PINs (C).
Viability heatmap images of heterocellular (PDAC + PCAF) spheroids following NIR photodynamic activation of TR-PINs with increasing
concentrations of the photosensitizer BPD-PC (D). Quantitation of fractional viability of spheroids following NIR photodynamic activation (100
J/cm2) using TR-PINs (E). (mean ± SEM; n = 9–12 for b−e; one-way ANOVA with a Tukey post-test; ∗∗∗∗P ≤ 0.0001, ∗∗∗P ≤ 0.001, ∗∗P ≤ 0.01).
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Figure 4: Expression of TR-PINs induced biological markers of immunogenic cell death in
Panc spheroid cultures. NIR activation of
TR-PINs induces cell surface exposure of
Hsp60, Hsp70, Calreticulin, and the intracellular expression of HMGB1 in Panc (MIA PaCa-2
and PCAF) spheroid cultures in a light dose and
time-dependent manner. Data are representative of three independent experiments done in
duplicates. Expression levels of Hsp60, Hsp70,
Calreticulin, and HMGB1 were determined by
flow cytometry calculated as the median fluorescence intensity (MFI) after subtraction of the
isotype controls MFI at 1, 6, 12, 24, 48, and 72 h
after NIR activation of TR-PINs. Graphs with
error bars indicate mean ± SEM from three independent experiments. Statistical signiﬁcance was determined by a one-way ANOVA
and Tukey's posthoc test. Asterisks denote
statistical signiﬁcance (*P < 0.05, **P < 0.005,
***P < 0.0005, ****P < 0.00005). The NIR
photodynamic activation regimen used was
690 nm light irradiation with 25 or 50 or 75 or
100 J/cm2 at 150 mW/cm2. Two hundred and
ﬁfty Newton-meters of TR-PINs (BPD-PC equivalent) were used.
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proteins in PDT treated cells can overwhelm the capacity of
Hsp-mediated proteolytic pathways to repair or remove the
abnormal proteins, leading to the formation of aggregates
that are toxic to the cells. Previous studies have demonstrated PDT-mediated expression of Hsp60 [12, 45] or
Hsp70 [12, 45–49] in various tumor cell line models in vitro.
Consistent with our results, those studies also showed a
temporal expression pattern of Hsps with more pronounced effects seen at highly cytotoxic PDT light doses
[12, 46–49]. As mentioned before, early expression of
membrane-bound Hsp60 and Hsp60 are powerful stimulants of antitumor immunity, helping to enhance TAAs and
tumor cell killing by cytotoxic CD8+ T cells [43, 44].
In our study, CRT expression was significantly upregulated at 12–24 h compared to untreated controls or
TR-PINs (Figure 4) without light activation, with peak
expression at 24 h with increasing light dose. HMGB1
expression showed a slower but steady increasing trend
from 1 to 72 h with high expression at 72 h in a light dosedependent manner (Figure 4). CRT is usually located in the
lumen of the endoplasmic reticulum, and it translocates to
the cell surface during an immunogenic response. The cell
surface expression of CRT sends “eat me” signals to
phagocytic immune cells such as macrophages or DCs and
helps these cells for the subsequent cross-presentation of
tumor antigens to T cells. In order to be detected by
phagocytic immune cells or other innate immune cells,
dying cells must emit signals in addition to CRT. The release
of HMGB1 from cancer cells undergoing ICD involves the
permeabilization of both the nuclear and the plasma
membranes that enables the translocation of the protein
from the nucleus to the cytoplasm, followed by freeing into
the extracellular space [50, 51]. Extracellular HMGB1 can
bind multiple cell surface receptors to induce immune
stimulation. PDT-mediated HMGB1 and CRT have been well
described in previous studies [46, 52–56]. In our analysis,
we were detecting intracellular HMGB1 levels which may
not reﬂect its release from dying cells. These data also show
that expression of Hsp60 and Hsp70 was more rapid
whereas CRT or HMGB1 showed delayed expression during
TR-PIN mediated ICD activation. The TR-PINs’ ability to
induce Hsp60, Hsp70, CRT, and HMGB1 shows the potency
of ICD in these pancreatic in vitro cultures and also highlights the possibility of immune stimulation.

2.4 TR-PINs mediated T cell activation and
antitumor reactivity
In order to study the NIR-TR-PINs activation of T cells, we
used Immune-Panc spheroids (Panc spheroids combined
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with immune cells; MIA PaCa-2-PCAF and PBMC) (Figure
5(A)). This model was set up based on previously published
protocols with slight modiﬁcations [57–60]. Allogenic
PBMC were isolated from healthy human buffy coats and
stimulated with anti-CD3 and anti-CD28 to mildly activate T
cells for three days. In parallel, Panc spheroids (MIA PaCa2-PCAFs) were cultured (1:1) for two days until they grew to
an optimum size. Then Panc spheroids were exposed to
TR-PIN mediated photodynamic activation on day 2 and
immediately, PBMC were added to the spheroid cultures
(Immune-Panc spheroids) with an effector (T cell) to target
(Panc spheroid cell) ratio of 5:1 and allowed to be in culture
in the presence of IL-2 for seven days [57, 58]. The medium,
including IL-2, was refreshed every three days. To
demonstrate that this system supports T cells priming and
expansion in vitro in the presence of Panc spheroids, we
quantiﬁed interferon-gamma (INFγ) [58, 61, 62] and the
degranulation of the cytolytic marker CD107a [58, 61–63]
on CD4+ T cells and CD8+ T cells at baseline (day 0 of
Immune-Panc spheroids in co-cultures), day 3 and day 7
using ﬂow cytometry; our gating strategies are shown in
the Supplementary Figure 4. We used TR-PINs at a concentration of 250 nM (the equivalent of BPD-PC) for all
experiments mentioned in this section with varying light
doses (25 or 50 or 75 or 100 J/cm2; 150 mW/cm2).
Light-induced activation of TR-PINs significantly
increased the number of both INFγ and CD107a expressing
CD4+ T cells (Figure 5(B)) and CD8+ T cells (Figure 5(C))
from day 0 to day 7 in co-cultures as compared to untreated
controls or T cells alone. This increase of INFγ and CD107a
positive T cells was more pronounced with increasing light
dose and time in culture. IFNγ is produced by T cells in
response to a variety of inﬂammatory or immune stimuli
and has shown particular importance in tumor immunosurveillance [61]. Tumor cells can be recognized and killed
by CD8+ effector T cells with help from CD4+ helper T cells,
mainly through the immune secretion of lytic granules that
kill target cells [64, 65]. This process involves the fusion of
the granule membrane with the cytoplasmic membrane of
the T cell, resulting in surface exposure of lysosomalassociated proteins that are typically present on the lipid
bilayer surrounding lytic granules, such as CD107a [66].
Therefore, membrane expression of CD107a indicates
cytotoxic degranulation and constitutes a marker of immune cell activation associated with antitumor immune
reactivity. Our data show that INFγ and CD107a are upregulated, thereby suggesting that TR-PINs mediated T cell
activation and enhanced effector antitumor reactivity. T
cell activation and antitumor immune reactivity induced
after PDT was reported in previous studies in preclinical
models. Wachowska et al. showed that Photofrin-PDT
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Figure 5: TR-PINs mediated priming of antitumor T cell reactivity in Immune-Panc spheroid co-cultures.
(A) MIA PaCa-2 and PACFs were cultured and allowed to grow for 48 h before co-culture with peripheral blood mononuclear cells (PBMC). PBMC
were seeded in 6-well plates with plate-bound anti-CD3 (overnight), anti-CD28, and IL-2, and T cells were allowed to proliferate for three days
before addition to 3D spheroid cultures. This was done using a previous protocol with slight modifications [57, 58]. Once the spheroids were
exposed to varying light doses, PBMC consisting mainly of mildly stimulated T cells were added to the cultures and allowed to remain for seven
days. T cell priming was evaluated at day 3 and 7 post-PDT by analyzing the surface expression of degranulation marker CD107a and
intracellular expression of INFγ. Also, in the same cultures, spheroid cell death was evaluated by ﬂow cytometry analysis on day 3. The
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leads to strong speciﬁc antitumor immune responses along
with increased production of IFNγ and upregulation of
CD107a in both CD4+ and CD8+ T lymphocytes of mice [63].
Another study that incorporated redaporﬁn-PDT in mice
bearing CT26 tumors demonstrated an increased percentage of IFNγ-producing CD4+ and CD8+ T cell populations,
highlighting the PDT mediated activation of antitumor T
cells [67]. Our data add to previous ﬁndings by showing
that priming and expansion of antitumor T cells are associated with the induction of ICD in pancreatic spheroid
cultures that mimic a tumor immune microenvironment.
The highest light dose that was successful in inducing
potent ICD response (Figure 4) was also able to show
enhanced T cell priming (Figure 5(B) and (C)).

2.5 Enhanced effects of PDT and T cellmediated tumor cell killing
Although TR-PINs were able to exert efficient cell killing at
the highest light doses in our initial experiments, we did
not find complete tumor cell killing by TR-PINs after PDT
(Figure 2(A)). Even at the highest dose of TR-PINs (1000 nM
equivalent of BPD-PC) and light (100 J/cm2; 150 mW/cm2),
there were about 20% of viable tumor cells in the Panc
spheroids at day 3 post-PDT (Figure 2(A)). Moreover, ∼60%
reduction in spheroid viability was also observed after PDT
with the TR-PINs (250 nM of BPD-PC equivalent) at a
similar light dose of 100 J/cm2 (Figure 2(D)). Thus, we
evaluated the enhanced effects of both PDP with TR-PINs
(250 nM of BPD-PC equivalent) and T cells (CD8+ T cells) to
exert efﬁcient cellular cytotoxicity. As depicted in the
schematic in Figure 5(A), tumor cell death in Immune-Panc
spheroids was evaluated on day 3 after NIR activation of
TR-PINs using ﬂow cytometry. Different cell death proﬁles
including necrotic, apoptotic, and dead cells were estimated with propidium iodide and annexin V staining as
shown in Figure 6(A). The percentage of apoptotic cells
was higher in Immune-Panc spheroids exposed to 75 J/cm2
compared to untreated controls (Figure 6(B)). However,
the percentage of dead cells was higher in Immune-Panc
spheroids cultures treated with 100 J/cm2, and the same
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cultures showed the highest percentage of complete cell
death (taken as the sum of apoptotic, necrotic, and dead
cells) by day 3 post-PDT. It is interesting to note that only
a minor fraction (<10%) of spheroid cells were viable at
day 3.
The remaining fraction of surviving Panc spheroid
cells could be a concern. However, reports of achieving
100% tumor cell death are not universal in twodimensional (2D) or 3D in vitro. There are many reasons
for this observation and heterogeneity even in cell lines
unless they have been carefully derived and maintained for
monoclonality. Cell killing in 3D models is typically less [8,
30, 68, 69], compared to tumor-killing efﬁciency in 2D
monolayer tumor models [70]. A possibility that some cells
were still alive in our Immune-Panc spheroids may be
attributed to the fact that the in vitro model used here is a
‘’hard to kill’’ 3D model as PCAFs support tumor cell
growth and possibly create dense desmoplastic 3D structures [71, 72]. PCAFs could elicit a strong immune suppressive effect on T cells that lead to their apoptosis
[73–75]. Finally, these are 3D models, recapitulating the
TME to a certain extent of the in vivo situation, thus the
distribution of PS and light are not identical from cell to
cell. All these factors bring heterogeneity adding resistance
to the outcome. However, it is interesting to note that
TR-PIN-mediated T cells activation achieving a signiﬁcant
level of tumor cell killing in our tumor spheroid model.
Further, T cells added to the in Immune-Panc spheroid cocultures are not autologous immune cells, which might
limit T cell’s ability to recognize tumor cells in our model.
Although we used a heterotypic 3D in vitro model of
PDAC, the tumor heterogeneity or antitumor immune effects of PDP are not completely recapitulated by this
model. Therefore, PDP-mediated immune-stimulatory
effects (local as well as systemic immune effects) could
be better understood in an in vivo experimental model.
Because PDP-mediated immune-stimulatory effects are
not limited to the area where light is applied; the immune
priming is that what extends well beyond the irradiated
site [3]. Previous studies in immunocompetent mouse
models show that PDP induces both the local antitumor
responses as well as subsequent systemic immune effects

expression of CD107a and INFγ from day 0 in culture to day 7 was evaluated in (B) CD4+ T cells and (C) CD8+ T cells using multi-color ﬂow
cytometry. Data are means ± SEM from three to four independent experiments done in duplicate. Statistical signiﬁcance was determined by a
one-way ANOVA and Tukey’s posthoc test. Asterisks denote statistical signiﬁcance (*P < 0.05, **P < 0.005, ***P < 0.0005). The NIR
photodynamic activation regimen consisted of 690 nm light irradiation with 25 or 50 or 75 or 100 J/cm2 at 150 mW/cm2. TR-PINs (BPD-PC
equivalent) were used at a concentration of 250 nM. All experimental conditions shown involved co-cultures Immune-Panc spheroids along
with the addition of the BPD-containing TR-PINs, except for one condition with PBMC only (T cell only), and another with untreated ImmunePanc spheroids with added immune cells but no photosensitizer (Unt + T cells).
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Figure 6: Synergistic effects on MIA PaCa-2 – PCAF cell killing by TR-PINs and antitumor reactive T cells.
Analysis of cell death was performed using Annexin V and Propidium Iodide (PI) staining. (A) As shown in the gating strategy for cell death
analysis, Panc spheroids were double-stained with Annexin V and PI and analyzed using flow cytometry. Four populations were identified as
viable cells, apoptotic cells, dead cells, and necrotic cells as indicated in the flow cytometry plots. Quantification of apoptotic cells, dead cells,
and total cell death (sum of apoptotic and dead cells including necrotic cells) under different culture conditions, is shown in figure (B). Data are
means ± SEM from three independent experiments done in duplicates. Statistical signiﬁcance was determined by a one-way ANOVA and
Tukey’s posthoc test. Asterisks denote statistical signiﬁcance (*P < 0.05). The NIR photodynamic activation regimen used 690 nm light
irradiation with 25 or 50 or 75 or 100 J/cm2 at 150 mW/cm2. TR-PINs (BPD-PC equivalent) were used at a concentration of 250 nM.
Key to conditions: Unt: untreated Panc spheroids (MIA PaCa-2 and PCAF) without T cells nor any nanoconstruct; No PDT: Panc spheroids with
TR-PINs alone but no illumination; Unt + T cells: untreated Panc spheroids with T cells (Immune-Panc spheroids); No PDT + T cells: ImmunePanc spheroids with TR-PINS without illumination; 25, 50, 25, 75, or 100 J/cm2: Panc spheroids with TR-PINS and PDT at the indicated dose of
light without T cells; 25 J/cm2 + T cells, 50 J/cm2 + T cells, 75 J/cm2 + T cells, or 100 J/cm2 + T cells; Immune-Panc spheroids with TR-PINS and PDT
at the indicated dose of light.

that take place at distant tumor sites [4, 76]. These systemic immune effects may be dependent on PDP’s ability
to expand an effector memory T cell pool [77, 78] supporting the notion that PDP’s ability to control the metastatic disease as evident by the preclinical tumor models [4,
76, 79–81]. In addition to the immune effects of PDP, there
could be other remote priming effects that could control
tumor metastases shown by our previous works in immunodeﬁcient mouse models of PDAC [20]. Huang et al.

demonstrated that PDP can mitigate drug delivery barriers
in the TME to safely enhance the therapeutic window of
FDA-approved nanoliposomal irinotecan in a preclinical
model of PDAC that also prevented tumor relapse [20].
PDP’s ability to augment efﬁcient drug delivery has been
attributed to enhanced vascular and stromal permeability
as shown by Obaid et al. [32]. Also, a consequent reduction
in metastatic burden, reported [20], possibly through the
regulation of CXCL12/CXCR7/CXCR4 axis [20, 22] which
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helps to normalize PCAFs preventing their involvement in
tumor metastases.

3 Conclusions
The enhancement of the DAMPs and T cells consequent to
PDP and how they impact the overall killing are examined in
this study using a complex heterogeneous 3D spheroid
model of PDAC either with or without immune cells. A
nanotechnology-enabled strategy, providing evidence that
TR-PINs intensifies PDT efficacy through the light doseenhancement effect in heterotypic Panc spheroids of PDAC
and PCAFs. PDP allowed not only effective uptake of the
targeted nanoconstructs but also the priming process
further to induced potent ICD highlighted by upregulation of
Hsp60, Hsp70, CRT, and HMGB1. ICD mediated enhanced
immunogenicity was able to efficiently prime CD4+ T cells
and CD8+ T cells evidenced by the upregulation of INFγ and
degranulation marker CD107a. These activated T cells
recognized tumor cells and provided further killing of
remaining MIA PaCa-2 and PCAF cells in Immune-Panc
spheroids. While priming effects for immune enhancement
with PDT have been reported previously, to our knowledge,
the effect of multiple targeted PDP has not been reported.
The triple receptor targeting, in addition to our ﬁndings of
immune stimulation also addresses tumor heterogeneity.
Although encouraging, much work is warranted in the
future to validate this approach, including testing in
appropriate in vivo models and quantifying the changes in
PS delivery and immune cell activation along with long-term
effects on survival.

4 Experimental section
Complete experimental details can be found in the Supplementary
Material.
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